NCT07546214CompletedPhase 1
A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis.
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study, Comparing Tapinarof Cream, 1% (Sun Pharma Canada, Inc.) and Vtama® (Tapinarof) Cream, 1% in the Treatment of Plaque Psoriasis.
Source: ClinicalTrials.gov · Last updated 22 Apr 2026
Brief summary (registry, in English)
To demonstrate therapeutic equivalence and safety of Tapinarof Cream, 1% (Sun pharma Canada, Inc.) and Vtama® (Tapinarof) Cream, 1% in the treatment of plaque psoriasis.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 575 (actual)
- First submitted
- 15 Apr 2026
- Start date
- 13 Oct 2025
- Primary completion date
- 18 Mar 2026
- Lead sponsor
- Sun Pharmaceutical Industries, Inc.
- Diseases
- Psoriasis
- NCT number
- NCT07546214
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 575
- From 13 Oct 2025 to the primary completion date, 18 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subjects with a current diagnosis of drug-induced psoriasis or unstable forms of psoriasis, including guttate, erythrodermic, exfoliative, or pustular psoriasis.
Other illness
- Subjects with a known hypersensitivity to tapinarof or to any ingredients in the study drugs.
Other
- Female Subjects who are pregnant, nursing, or planning to become pregnant during study participation.
- Subjects with spontaneously improving or rapidly deteriorating plaque psoriasis or pustular psoriasis as determined by the investigator.
Who the study is looking for
- Healthy male or non-pregnant female aged ≥ 18 years with a clinical diagnosis of plaque psoriasis.
- Subjects must have provided IRB approved written informed consent.
- Subjects must have a clinical diagnosis of stable (at least 6 months) plaque psoriasis involving 3% to 20% body surface area (BSA), not including the face, scalp, groin, palms, fingernails, toenails, and soles in the BSA calculation.
- Subjects must have plaque psoriasis with a Physician's Global Assessment (PGA) score of 2 (mild), 3 (moderate), or 4 (severe)
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sun Pharmaceutical Industries, Inc. Coordinator of this site? Confirm its status | Hawthorne | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.